These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34277913)

  • 41. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.
    Rzany B; Correia O; Kelly JP; Naldi L; Auquier A; Stern R
    Lancet; 1999 Jun; 353(9171):2190-4. PubMed ID: 10392983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?
    Tartarone A; Lerose R
    Ther Drug Monit; 2010 Dec; 32(6):669-72. PubMed ID: 20844465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013.
    Suwarsa O; Yuwita W; Dharmadji HP; Sutedja E
    Asia Pac Allergy; 2016 Jan; 6(1):43-7. PubMed ID: 26844219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Abe R
    J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.
    Mockenhaupt M; Messenheimer J; Tennis P; Schlingmann J
    Neurology; 2005 Apr; 64(7):1134-8. PubMed ID: 15824335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective study of 185 cases in Abidjan (Côte d'Ivoire)].
    Kourouma S; Sangaré A; Kaloga M; Kouassi I; Ecra E; Gbery I; Ahogo C; Kouassi A; Kassi K; Camara B
    Med Sante Trop; 2014; 24(1):94-8. PubMed ID: 24736218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
    Antoon JW; Goldman JL; Shah SS; Lee B
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):244-250.e1. PubMed ID: 29859332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progression of toxic epidermal necrolysis after tanning bed exposure.
    Gatson NT; Travers JB; Al-Hassani M; Warren SJ; Hyatt AM; Travers JB
    Arch Dermatol; 2011 Jun; 147(6):719-23. PubMed ID: 21339416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database.
    Abe J; Umetsu R; Mataki K; Kato Y; Ueda N; Nakayama Y; Hane Y; Matsui T; Hatahira H; Sasaoka S; Motooka Y; Hara H; Kato Z; Kinosada Y; Inagaki N; Nakamura M
    J Pharm Health Care Sci; 2016; 2():14. PubMed ID: 27330825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study.
    Chow LLW; Shih KC; Chan JCY; Lai JSM; Ng ALK
    BMC Ophthalmol; 2017 May; 17(1):65. PubMed ID: 28499410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!
    Kumar R; Das A; Das S
    Indian J Dermatol; 2018; 63(2):117-124. PubMed ID: 29692452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    El-Azhary RA; Nowsheen S; Gibson LE; DiCaudo DJ
    Int J Dermatol; 2021 Feb; 60(2):185-189. PubMed ID: 33332598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chen CB; Chang WC; Wu MY; Kao TY; Wang YW; Wang CW; Chen CJ; Chung WH; Su SC
    Int J Biol Sci; 2020; 16(2):353-364. PubMed ID: 31929762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hasegawa A; Abe R
    F1000Res; 2020; 9():. PubMed ID: 32595945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.